Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...

It's been a sad week for Vertex, Inc. ( NASDAQ:VERX ), who've watched their investment drop 14% to US$20.08 in the ...

Jupiter Endovascular today announced positive results from the first-in-human study of its Vertex pulmonary embolectomy ...

Both companies are leaders in their niche with excellent growth prospects. They could deliver market-beating returns through ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Google is planning to ship two new models. One is Gemini 3, which is optimised for coding and regular use, and the second is ...